Granted Patent
B2
US 12,324,828 · App. 18/114,710 · Granted Jun 10, 2025
Conjugates of a factor VIII moiety having an oxime-containing linkage
Assignee:
Nektar Therapeutics
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides conjugates comprising a Factor VIII moiety covalently attached via an oxime-containing linkage to a water-soluble polymer, such as for example, a polyethylene glycol polymer. Methods for preparing and for administering such conjugates, are also provided, as are water-soluble polymer oxyamine reagents useful for preparing the subject conjugates, among other things.
Claims (5)
1. A polymeric oxyamine reagent having a structure selected from:
where X is-NH(CH 2 ) 1-6 NHC(O)CH 2 —, and each (n) ranges from about 1 to about 4,000.
2. The polymeric oxyamine reagent of claim 1 , wherein X is —NH(CH 2 ) 2 NHC(O)CH 2 —.
3. The polymeric oxamine reagent of claim 1 , wherein each (n) is about 227.
4. The polymeric oxamine reagent of claim 1 , wherein each (n) is selected such that the weight average molecular weight of the branched poly(ethylene glycol) polymer ranges from greater than 5,000 Daltons to 100,000 Daltons.
Continuity (3)
Division
16319759
Provisional Application
62365836
· Jul 22, 2016
References Cited (71)
US 4868122A
· Kominek et al.
· 1989
[cited by applicant]
US 5629384A
· Veronese et al.
· 1997
[cited by applicant]
US 5932462A
· Harris et al.
· 1999
[cited by applicant]
US 6158888A
· Walker et al.
· 2000
[cited by applicant]
US 6362254B2
· Harris et al.
· 2002
[cited by applicant]
US 7199223B2
· Bossard et al.
· 2007
[cited by applicant]
US 20030077752A1
· Cho et al.
· 2003
[cited by applicant]
US 20100197573A1
· Dorwald
· 2010
[cited by examiner]
US 20140107320A1
· Haider et al.
· 2014
[cited by applicant]
US 20170210777A1
· Minami
· 2017
[cited by applicant]
EP 1688150A1
· 2006
[cited by applicant]
WO WO2008025856A2
· 2008
[cited by applicant]
WO WO2011017055A2
· 2011
[cited by applicant]
WO WO2012016131A1
· 2012
[cited by applicant]
WO WO2015186988A1
· 2015
[cited by applicant]
WO WO2016036794A1
· 2016
[cited by applicant]
English Translation of Chinese Rejection Decision corresponding to Chinese Patent Application No. 201780045001.X date of notification Nov. 7, 2022.
[cited by applicant]
English Translation of Korean Grounds for Final Rejection corresponding to Korean Patent Application No. 10-2019-7003562 issuance date Dec. 1, 2022.
[cited by applicant]
English Translation of Korean Grounds for Final Rejection corresponding to Korean Patent Application No. 10-2019-7003562 issuance date May 12, 2023.
[cited by applicant]
Agerso et al., “Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs”, Haemophilia, vol. 18, pp. 941-947, (2012).
[cited by applicant]
Albrecht et al., “Simple Preparation of O-Substituted Hydroxylamines from Alcohols”, Synthesis, No. 10, pp. 1635-1638 (2006).
[cited by applicant]
Bader et al., “Polysialic acid: overcoming the hurdles of drug delivery”, Ther. Deliv., vol. 5, No. 3, pp. 235-237, (2014).
[cited by applicant]
Baldwin et al., “Synthesis of Polymer-Bound Hemoglobin Samples”, Tetrahedron, vol. 37, pp. 1723-1726, (1981).
[cited by applicant]
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, vol. 66, No. 1, pp. 1-19, (Jan. 1977).
[cited by applicant]
Caliceti et al., “Synthesis and Physicochemical Characterization of Folate-Cyclodextrin Bioconjugate for Active Drug Delivery”, Bioconjugate Chem., vol. 14, pp. 899-908, (2003).
[cited by applicant]
Harris et al., “Effect of Pegylation on Pharmaceuticals”, Nature Reviews, vol. 2, pp. 214-222, (Mar. 2003).
[cited by applicant]
Kaneda et al., “The use of PVP as a polymeric carrier to improve the plasma half-life of drugs”, Biomaterials, vol. 25, pp. 3259-3266, (2004).
[cited by applicant]
Lenting et al., “The disappearing act of factor VIII”, Haemophilia, vol. 16, pp. 6-15, (2010).
[cited by applicant]
Lenting et al., “The Life Cycle of Coagulation Factor VIII in View of Its Structure and Function”, Blood, vol. 92, No. 11, pp. 3983-3996, (Dec. 1, 1998).
[cited by applicant]
Mertens et al., “Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys
[cited by applicant]
Ostergaard et al., “Prolonged half-life and preserved enzymatic properties of factor IX selectivity PEGylated on native N-glycans in the activation peptide”, Blood, vol. 118, No. 8, pp. 2333-2341, (2011).
[cited by applicant]
Peschke et al., “C-Terminally PEGylated hGH-derivatives”, Bioorganic & Medicinal Chemistry, vol. 15, pp. 4382-4395, (2007).
[cited by applicant]
Powell et al., “Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A”, Journal of Thrombosis and Haemostasis, vol. 6, pp. 277-283, (2008).
[cited by applicant]
Powell, et al., “Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients”, Blood, vol. 119, No. 13, pp. 3031-3037, (2012).
[cited by applicant]
Schulte, “Pioneering designs for recombinant coagulation factors”, Thrombosis Research, vol. 128, Suppl 1, pp. S9-S12, (2011).
[cited by applicant]
Sims et al., “A Method for the Estimation of Polyethylene Glycol in Plasma Protein Fractions”, Analytical Biochemistry, vol. 107, pp. 60-63, (1980).
[cited by applicant]
Slichter et al., “Preparation of Cryoprecipitated Factor VIII Concentrates”, Transfusion, vol. 16, No. 6, pp. 616-626, (Nov.-Dec. 1976).
[cited by applicant]
Stennicke et al., “A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models”, Blood, vol. 121, No. 11, pp. 2108-2116, (Mar. 14, 2013).
[cited by applicant]
Stennicke et al., “Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives”, Thromb. Haemost., vol. 100, pp. 920-928, (2008).
[cited by applicant]
Szmitkowski et al., “Antihaemophilic Factor (Factor VIII) from Human Granulocytes”, Haemotologia, vol. 11, No. 1-2, pp. 177-187, (1977).
[cited by applicant]
Tiede, et al., “Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A”, J. Thromb. Haemost., vol. 11, pp. 670-6…
[cited by applicant]
Turecek et al., “BAX 855, a PEGylated rFVIII product with prolonged half-life”, Hamostaseologie, vol. 32, Suppl 1, pp. S29-S38, (2012).
[cited by applicant]
Turecek et al., “PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs”, Journal of Pharmaceutical Sciences, vol. 105, pp. 460-475, (2016).
[cited by applicant]
Wickerhauser, “Preparation of Antihemophilic Factor from Indated Plasma”, Transfusion, vol. 16, No. 4, pp. 345-350, (Jul.-Aug. 1976).
[cited by applicant]
Wolfe et al., “Studies on the Rate and Control of Antibody Oxidation by Periodate”, Analytical Biochemistry, vol. 231, pp. 123-130, (1995).
[cited by applicant]
PCT International Search Report corresponding to PCT Application No. PCT/US2017/043221 dated Jan. 25, 2018.
[cited by applicant]
PCT International Preliminary Report on Patentability corresponding to PCT Application No. PCT/US2017/043221 date of mailing Jan. 31, 2019.
[cited by applicant]
English Translation of Notification of the First Office Action corresponding to Chinese Patent Application No. 201780045001.X date of notification Aug. 31, 2021.
[cited by applicant]
English Translation of Notification of the Second Office Action corresponding to Chinese Patent Application No. 201780045001.X date of notification Mar. 30, 2022.
[cited by applicant]
European Communication corresponding to European Patent Application No. 17 748 993.7 date Jan. 28, 2021.
[cited by applicant]
English Translation of Notice of Reasons for Rejection corresponding to Japanese Patent Application No. 2019-502676 mailing date Jul. 26, 2021.
[cited by applicant]
English Translation of Notice of Final Rejection corresponding to Japanese Patent Application No. 2019-502676 mailing date May 31, 2022.
[cited by applicant]
English Translation of Notice of Grounds for Rejection corresponding to Korean Patent Application No. 10-2019-7003562 issuance date Jun. 23, 2022.
[cited by applicant]
Enzon Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).
[cited by applicant]
NEKTAR™—Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog—2003, (Jul. 2003).
[cited by applicant]
NEKTAR™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog—2004, (Jul. 2004).
[cited by applicant]
NEKTAR™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages, (Catalog 2005—2006).
[cited by applicant]
NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003—1
[cited by applicant]
NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003—2
[cited by applicant]
NOF Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).
[cited by applicant]
Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2004).
[cited by applicant]
Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2005).
[cited by applicant]
Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG™, 38 pages, (Mar. 12, 2004).
[cited by applicant]
Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG™ Technology, 31 pages, (Nov. 5, 2004).
[cited by applicant]
Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).
[cited by applicant]
Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).
[cited by applicant]
Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog—(Mar. 1995).
[cited by applicant]
Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).
[cited by applicant]
Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog—(Jan. 2000).
[cited by applicant]
Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog—(Jul. 2001).
[cited by applicant]